Table 2.
S‐ICD Implant Characteristics in ARVC/D Patients
| Clinical Variables | Overall Population (N=29) | Primary Prevention (n=17) | Secondary Prevention (n=12) |
|---|---|---|---|
| S‐ICD device model | |||
| First generation | 13 (45) | 6 (35) | 7 (58) |
| Second generation | 16 (55) | 11 (65) | 5 (42) |
| Defibrillation testing attempted | 29 (100) | 17 (100) | 12 (100) |
| VF induced | 27(93) | 17 (100) | 10 (83) |
| Acute VF conversion | 27/27 (100) | 17/17 (100) | 10/10 (100) |
| S‐ICD programming | |||
| Conditional zone, bpm, mean (range) | 207 (190–230) | 208 (190–230) | 207 (190–220) |
| Shock zone, bpm, mean (range) | 242 (220–250) | 243 (230–250) | 241 (220–250) |
| Perioperative complications | |||
| S‐ICD system infection | 0 | 0 | 0 |
| Hematoma | 0 | 0 | 0 |
| Inappropriate shock: oversensing | 0 | 0 | 0 |
| Superficial/incisional‐related infection | 2 (7) | 0 | 2 (17) |
| Need for revision because of lead/device movement | 0 | 0 | 0 |
| Suspected device malfunction | 0 | 0 | 0 |
| Pneumothorax | 0 | 0 | 0 |
Values are n (%), n/N (%), or median (interquartile range). ARVC/D indicates arrhythmogenic right ventricular cardiomyopathy/dysplasia; S‐ICD, subcutaneous implantable cardioverter‐defibrillator; VF, ventricular fibrillation.